



ABN 82 010 975 612

Level 18, 101 Collins Street  
Victoria 3000 Australia  
Telephone: + 61 7 3273 9133  
Facsimile: + 61 7 3375 1168  
[www.tbgbio.com](http://www.tbgbio.com)

12 May 2017

## **ASX Announcement Results of Meeting**

In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders TBG Diagnostics Limited ("Company") at its 2016 Annual General Meeting of shareholders held on 12 May 2017.

All resolutions put to the meeting were passed on a show of hands. The Company received 151,401,479 valid proxy votes in respect of each resolution. The Chairman voted all undirected proxies held at his discretion in favour of each resolution. The instructions given to validly appointed proxies in respect of the resolutions were as follows:

<b>Resolution</b>	<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Chairman's Discretion</b>	<b>Excluded</b>
1. Remuneration Report	4,920,036	305,865	37,956	21,684	146,115,938
2. Re-elect Director Jitto Arulampalam	151,116,090	213,464	50,241	21,684	Nil
3. Re-elect Director Stanley Chang	151,232,803	132,885	14,107	21,684	Nil
4. Approve Additional Share Issue Capacity Under ASX Listing Rule 7.1A	151,155,758	209,859	13,113	22,749	Nil

For more information:

Justyn Stedwell  
Company Secretary  
+ 61 7 3273 9133

### **About TBG Diagnostics**

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020.

Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases.